(2E,4E,6E,8E)-9-(2-acetyl-5,5-dimethylcyclopenten-1-yl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid | 50890-42-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: (2E,4E,6E,8E)-9-(2-acetyl-5,5-dimethylcyclopenten-1-yl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
• CAS: 50890-42-1
• 化学式: C₂₀H₂₆O₃
• 分子量: 314.425
• InChiKey: FSLMGODKGHHERM-FRCNGJHJSA-N

物化性质

• 沸点：
  508.7±33.0 °C(Predicted)
• 密度：
  1.081±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  methyl 5,6-dioxo-5,6-secoretinoate 生成 (2E,4E,6E,8E)-9-(2-acetyl-5,5-dimethylcyclopenten-1-yl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid
  参考文献：
  名称：

  摘要：

  A method of simultaneous one-stage synthesis of three retinal derivatives (5,6-dioxo-5,6-seco-, 5,6-dihydro-5,6-epoxy-, and 4-oxoretinal) was proposed, with the yield of the first derivative being similar to50%. These compounds are useful tools for studying the antitumor activity of retinoids, the reconstituted bacteriorhodopsin analogues with changed parameters of photocycle, and the reactivity of retinal derivatives in the processes of oxidation by molecular oxygen.

  DOI：

  10.1023/a:1021245616117

文献信息

• Oleaginous pharmaceutical and cosmetic foam
  申请人：Tamarkin Dov

  公开号：US20070292461A1

  公开（公告）日：2007-12-20

  The invention relates to stable pharmaceutical or cosmetic foam compositions containing certain active agents, having unique therapeutic properties and methods of treatment using such compositions. The foamable composition includes at least one solvent comprising polyethylene glycol (PEG) or PEG derivative and mixtures thereof, or comprising propylene glycol, wherein the solvent is present at a concentration of about 70% to about 96.5% by weight of the total composition, at least a non-ionic surface-active agent at a concentration of about 0.1% to less than about 10% by weight of the total composition.
• QUIESCENT FOAMABLE COMPOSITIONS, STEROIDS, KITS AND USES THEREOF
  申请人：TAMARKIN Dov

  公开号：US20080206161A1

  公开（公告）日：2008-08-28

  The present invention relates to an emulsion steroid composition as a foamable vehicle in which the vehicle is stable or stabilized by the presence of at least one quiesence agent; therapeutical kit containing such composition; to methods of treatment using such composition; to methods of enhancing the stability of such composition.
• SILICONE IN GLYCOL PHARMACEUTICAL AND COSMETIC COMPOSITIONS WITH ACCOMMODATING AGENT
  申请人：TAMARKIN Dov

  公开号：US20080292560A1

  公开（公告）日：2008-11-27

  A carrier, composition or foam formulation comprising; a silicone; about 25% to about 98% of a solvent selected from the group consisting of (1) a propylene glycol or derivative and (2) a polyethylene glycol (PEG) or derivative or mixtures thereof; 0% to about 48% of at least one secondary solvent; and an Accommodating Agent or Complex; and methods of treatment. A hygroscopic silicone in glycol containing composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and a therapeutic agent.
• HYDROPHILIC, NON-AQUEOUS PHARMACEUTICAL CARRIERS AND COMPOSITIONS AND USES
  申请人：Tamarkin Dov

  公开号：US20080299220A1

  公开（公告）日：2008-12-04

  A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said hydrophilic solvent selected from the group consisting of (i) a mixture of two or more different polyethylene glycols (PEGs), wherein at least one PEG is a high molecular weight PEG having a melting point greater than 25° C.; and (ii) propylene glycol (PG); about 0% to about 10% of at least one surface active agent; about 0% to about 5% of a polymeric agent; about 0% to about 30% of a secondary hydrophilic solvent; and about 0% to about 5% of a silicone oil; and about 3% to about 25% hydrophobic propellant. The composition is otherwise substantially free of a hydrophobic solvent and includes at least one of a surface active agent and a polymeric agent. The vehicle and the propellant are sufficiently miscible that the components may be homogeneously distributed with mild shaking.
• TETRACYCLINE MANAGEMENT OF EGFR INHIBITOR ASSOCIATED DERMATOSES
  申请人：Foamix Pharmaceuticals Ltd.

  公开号：US20190307778A1

  公开（公告）日：2019-10-10

  Methods of treatment and dosage regimes using a composition comprising a tetracycline antibiotic in treating or alleviating a disorder including EGFRI associated rash, EGFRI associated rash related symptoms, a tetracycline antibiotic responsive EGFRI associated rash related disorder, skin disorder caused by a bacteria, and a tetracycline antibiotic responsive sebaceous gland disease, P. EGFRI associated rash bacteria associated disorders and other superficial infections, including skin infections are provided.